2 Jan 2024 • Plasma calprotectin levels were studied for associations with the risk of new‐onset hypertension, defined as systolic blood pressure of at least 140 mm Hg, diastolic blood pressure of at least 90 mm Hg, or the first recorded use of antihypertensives.

Elevated levels of plasma calprotectin were linked to a heightened likelihood of developing new-onset hypertension in the general population.

This risk correlation was influenced by the baseline SBP & was more significant in men than in women.

Individuals with increased urinary albumin excretion (>9.3 mg per 24 hours) faced a greater risk compared to those with lower urinary albumin excretion (≤9.3 mg per 24 hours).

These findings support the potential usefulness of plasma calprotectin as a biomarker for the future development of hypertension, albeit validation and longitudinal assessments across various stages of hypertension are needed to further establish its definitive role in clinical practice.

Source: JACC | Read full story